v3.21.2
Condensed Consolidated Statement of Cash Flows - USD ($)
9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Cash Flows from Operating Activities    
Net loss $ (4,052,290) $ (4,898,685)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 13,859 69,447
Amortization of debt discount 1,395,007
Forgiveness of PPP loan (698,820)
Issuance of warrants to extend convertible debt 17,636
Issuance of warrants pursuant to short-term notes, related party (1,300,088)
Issuance of warrants to extend short-term debt 6,595
Share based compensation expense 1,024,359 643
Common stock issued for consulting services 35,000
Change in fair value of derivative liability - warrants (2,986,853)
Change in fair value of derivative liability - warrants (272,705)
Change in fair value of derivative liability - Day one derivative loss 2,306,121
Warrant modification expense 70,851
Loss on disposal of property and equipment 92,804
Changes in operating assets and liabilities:    
Accounts receivable (9,200) 20,167
Patient financing receivable, current portion (35,080)
Other receivables 21,572 16,372
Patient financing receivable, net of current portion (61,547)
Prepaid expenses and other assets (968) 707,457
Interest payable 6,333 35,565
Accounts Payable 37,759 (237,409)
Accrued liabilities (89,296) (21,206)
Other current liabilities (13,482) (15,680)
Deferred revenue (224,118) (409,375)
Net Cash Used in Operating Activities (3,988,115) (5,461,140)
Cash Flows from Investing Activities    
Purchase of property and equipment (7,832) (2,285)
Net Cash Used in Investing Activities (7,832) (2,285)
Cash Flows from Financing Activities    
Proceeds from convertible notes payable, related parties 1,584,665
Proceeds from convertible notes payable 1,091,080
Proceeds from PPP loan 809,082
Payments on PPP Loan (13,230) (10,937)
Proceeds from warrants, net of issuance costs 3,842,695
Proceeds from issuance of Preferred Stock Series A, net of issuance costs 2,735,736
Proceeds from issuance of Series D Convertible Preferred Stock 100,000
Net Cash Provided by Financing Activities 2,662,515 7,476,576
Net Change in Cash (1,333,432) 2,013,151
Cash - Beginning of period 1,640,645 1,424,096
Cash - End of period 307,213 3,437,247
Supplementary Cash Flow Information    
Cash paid for interest 3,367 17,066
Non-cash investing and financing activities    
Deemed Dividend on Series D Convertible Preferred Stock 314,926
Conversion of Series D Preferred Stock to Common Stock 6,438,214
Conversion of related party (Horne) warrants to equity 107,123
Reclassification of Series B warrants to equity 73,805
Reclassification of Series D warrants to equity 337,400
Issuance of Common Stock in exchange for consulting fees 35,000
Issuance of warrants to extend short-term debt 6,595
Issuance of warrants pursuant to extension of convertible short-term notes 17,636
Conversion of Series B Preferred Stock to Common Stock 153,097
Conversion of short-term related party convertible notes to Preferred Stock 412,541
Conversion of short-term convertible notes to Preferred Stock 4,751,484
Dividends accrued on Series B Preferred Stock 44,456
Adjustment of exercise price on convertible debt 438,913
Issuance of Common Stock in connection with extinguishment of short-term notes, related parties 218,414
Issuance of Warrants in connection with Series D Convertible Preferred Stock $ 31,902

Source